Three years ago, drug-eluting stents (DES) took such hold of the interventional cardiology community and the development programs of the medical device companies that served them that there didn’t seem to be room for anything else when it came to restoring flow to blocked blood vessels. But the honeymoon is over. Experience has shown that drug-eluting stents aren’t suitable for a large number of types of patients and lesions—they’re ineffective for certain patients with diabetes or small vessels, bifurcated lesions or lesions in peripheral vessels.
Drug-Eluting Balloons: New Route to Revascularization
A few companies with the foresight, even during the heyday of drug-eluting stents, to begin developing drug-eluting balloons are well-positioned to capture one of the next enormous growth markets in cardiology, according to "Current and Emerging US Markets for Myocardial Revascularization, Repair, and Regeneration Products and Technologies," a report recently published by the Medtech Insight division of FDC-Windhover.
More from Archive
More from Medtech Insight
• By
A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.
• By
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
• By
Through this partnership, data stored in LibreView – Abbott’s cloud-based diabetes data management system – can automatically flow into Epic, allowing clinicians using Epic to view a patient’s CGM data before, during and after visits without toggling between systems or requesting manual uploads.